Écrit par GBI Research | 14 Février 2017

Roche will be the biggest mover in the neurodegenerative drugs space over the next five years, with the anticipated approval of ocrelizumab driving the company’s share of the market from less than 1% in 2016 to approximately 15% by 2022, according to business intelligence provider GBI Research.

The company’s report states that while Roche will make significant gains, Biogen will remain the...

Écrit par Pixium | 14 Février 2017

Paris, France - 14 février 2017 - Pixium Vision, société qui développe des systèmes de vision bionique innovants pour permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce aujourd'hui que l'Institut du Système de Rémunération Hospitalier Allemand (InEK) a accordé le Statut-1 du NUB (Neue Untersuchungs- und Behandlungsmethoden) à IRIS®II - premier...

Écrit par GlobalData | 08 Février 2017

The hepatitis C market is set to experience a steady decline, falling from $21.7 billion in 2015 to $17.5 billion by 2025, representing a negative compound annual growth rate of 2.1%, according to research and consulting firm GlobalData.

The company’s report states that this deterioration in sales, which will occur across the nine major markets (9MM) of the US, France, Germany, Italy...

Écrit par GBI Research | 08 Février 2017

Changing physician, patient, and consumer trends in today’s increasingly digital society are forcing an evolution of pharmaceutical marketing strategies, according to business intelligence provider GBI Research.

The company’s latest CBR Pharma Insights report states that while the pharmaceutical field is renowned for experimenting with cutting-edge technology to facilitate medical...